BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetic/pharmacodynamic modelling in oncological drug development. 2005

Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Box 591, SE-751 24 Uppsala, Sweden. mats.karlsson@farmbio.uu.se

For many oncological agents, myelosuppression is the dose-limiting toxicity and the quantitative characterisation of the relationship between drug dose, plasma concentration and haematological toxicity is of importance in the drug development. Mechanism-based population pharmacokinetic-pharmacodynamic models have been developed for this purpose and the applications of these in candidate selection, first-in-man studies, prodrug and formulation development, dose finding, schedule optimisation, assessing influence of modifying agents, drug combination studies, subgroup identification and feedback individualisation are reviewed.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Pharmacokinetic and pharmacodynamic modelling in drug development.
September 1999, Statistical methods in medical research,
Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development.
November 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Pharmacokinetic/ pharmacodynamic-driven drug development.
January 2010, The Mount Sinai journal of medicine, New York,
Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Pharmacokinetic/pharmacodynamic modeling in drug development.
January 2000, Annual review of pharmacology and toxicology,
Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
[Pharmacokinetic and pharmacodynamic modelling in paediatric drug development with a focus on physiology-based pharmacokinetic simulations].
May 2019, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen,
Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses.
January 2023, Expert review of clinical pharmacology,
Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Pharmacokinetic-pharmacodynamic modelling in anaesthesia.
January 2015, British journal of clinical pharmacology,
Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Pharmacokinetic/pharmacodynamic studies in drug product development.
January 2002, Journal of pharmaceutical sciences,
Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.
July 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Mats O Karlsson, and Therese Anehall, and Lena E Friberg, and Anja Henningsson, and Charlotte Kloft, and Marie Sandström, and Rujia Xie
Pharmacokinetic/pharmacodynamic modelling of atracurium.
January 1993, British journal of anaesthesia,
Copied contents to your clipboard!